Kancera AB (publ) Stock Forecast for 2023 - 2025 - 2030
Updated on 05/04/2024
Kancera AB (publ) Stock Forecast and Price Target
Kancera AB (publ)'s stock price reaches the average target of kr5.00 by 2025 as expected recently by notable experts, there would be a potential upside of approximately 228.95% from the last closing price in May, 2024. This possible increase is based on a high estimate of kr5.00 and a low estimate of kr5.00. Even if you're not interested in KAN stock, you may be interested in its competitors.
228.95% Upside
Kancera AB (publ) Fair Value Forecast for 2023 - 2025 - 2030
In the last zero years, Kancera AB (publ)'s Price has grown by 100.00%, from kr0.00 to kr0.00. For the next year, analysts are expecting Fair Value to reach kr3.00 – an increase of 100.00%. Over the next seven years, experts predict that Fair Value will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SOBI Stock Forecast | Swedish Orphan Biovitrum AB (p... | Outperform |
16
|
kr280.00 | Buy/Sell | kr293.00 | 16.07% |
| VITR Stock Forecast | Vitrolife AB (publ) | Buy |
18
|
kr175.20 | Buy/Sell | kr250.00 | 25.57% |
| BIOA B Stock Forecast | BioArctic AB (publ) | Outperform |
10
|
kr193.60 | Buy/Sell | kr372.40 | 80.79% |
| KARO Stock Forecast | Karo Healthcare AB | - |
12
|
kr60.70 | Buy/Sell | kr40.00 | -100.00% |
| GENO Stock Forecast | Genovis AB (publ.) | Outperform |
16
|
kr29.05 | Buy/Sell | kr75.67 | 73.84% |
Kancera AB (publ) Revenue Forecast for 2023 - 2025 - 2030
In the last year, Kancera AB (publ)'s Revenue has grown by 1788.89%, from kr90.00k to kr1.70M. In the next year, 0 analysts estimate that Kancera AB (publ)'s Revenue will decrease by 94.71%, reaching kr89.93k. Over the next nine years, experts predict that Revenue will grow by 2518.98%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BINV Stock Forecast | BioInvent International AB (pu... | Outperform |
10
|
kr26.95 | Buy/Sell | kr107.00 | 207.98% |
| VICO Stock Forecast | Vicore Pharma Holding AB (publ... | Buy |
4
|
kr19.24 | Buy/Sell | kr70.75 | 237.84% |
| HNSA Stock Forecast | Hansa Biopharma AB (publ) | Buy |
6
|
kr29.74 | Buy/Sell | kr123.00 | 216.07% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| XSPRAY Stock Forecast | Xspray Pharma AB (publ) | Outperform |
6
|
kr41.95 | Buy/Sell | kr120.00 | 155.07% |
| MERT A Stock Forecast | Mertiva AB (publ) | - |
9
|
kr0.00 | Buy/Sell | kr0.00 | 0.00% |
| IMMNOV Stock Forecast | Immunovia AB (publ) | - |
0
|
kr1.94 | Buy/Sell | kr0.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ATORX Stock Forecast | Alligator Bioscience AB (publ) | Outperform |
0
|
kr0.92 | Buy/Sell | kr1.83 | 150.00% |
| CANTA Stock Forecast | Cantargia AB (publ) | Buy |
5
|
kr3.42 | Buy/Sell | kr13.67 | 280.12% |
| XBRANE Stock Forecast | Xbrane Biopharma AB (publ) | Outperform |
5
|
kr0.20 | Buy/Sell | kr116.00 | 215.00% |
Kancera AB (publ) EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Kancera AB (publ)'s EBITDA has grown by 4.53%, rising from kr-50.10M to kr-52.37M. 1 analysts predict Kancera AB (publ)'s EBITDA will decrease by 128.45% in the next year, reaching kr14.90M. Over the next seven years, experts predict that Kancera AB (publ)'s EBITDA will grow at a rate of 1435.24%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IMMU Stock Forecast | Mendus AB (publ) |
9
|
kr0.47 | Buy/Sell | kr1.70 | 282.98% | |
| ACE Stock Forecast | Ascelia Pharma AB (publ) |
0
|
kr11.76 | Buy/Sell | kr19.50 | -17.09% | |
| KDEV Stock Forecast | Karolinska Development AB (pub... |
8
|
kr1.58 | Buy/Sell | kr4.70 | 156.33% |
Kancera AB (publ) EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Kancera AB (publ)'s EBIT has grown, rising from kr-51.68M to kr-52.69M – a growth of 1.95%. For the following year, the 1 analysts predict that Kancera AB (publ)'s EBIT will drop by 128.28%, reaching kr14.90M. In 2030, the professionals' prediction is that KAN's EBIT will decrease by 411.06%, reaching kr163.90M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ISR Stock Forecast | ISR Immune System Regulation H... | - |
0
|
kr7.43 | Buy/Sell | kr0.00 | -100.00% |
| HAMLET B Stock Forecast | Hamlet BioPharma AB (publ) | - |
0
|
kr2.77 | Buy/Sell | kr0.00 | -100.00% |
| ONCO Stock Forecast | Oncopeptides AB (publ) |
0
|
kr2.98 | Buy/Sell | kr6.90 | 114.77% |
Kancera AB (publ) EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last zero years, Kancera AB (publ)'s EPS has grown by 100.00%, from kr0.00 to kr0.00. For the next year, analysts are expecting EPS to reach kr0.20 – an increase of 100.00%. Over the next seven years, experts predict that EPS will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GUARD Stock Forecast | Guard Therapeutics Internation... |
8
|
kr30.00 | Buy/Sell | kr0.23 | 116.67% | |
| IVACC Stock Forecast | Intervacc AB (publ) |
10
|
kr4.34 | Buy/Sell | kr27.00 | 84.33% | |
| SYNACT Stock Forecast | SynAct Pharma AB | - |
7
|
kr6.66 | Buy/Sell | kr15.00 | -100.00% |
.jpg)